Market Size of Biopharmaceuticals Industry
![Biopharmaceuticals Market Summary](https://s3.mordorintelligence.com/global-biopharmaceuticals-market-industry/1706635756542_global-biopharmaceuticals-market-industry_Market_Summary.webp)
Study Period | 2021 - 2029 |
Market Size (2024) | USD 516.79 Billion |
Market Size (2029) | USD 761.80 Billion |
CAGR (2024 - 2029) | 8.07 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Biopharmaceuticals Market Analysis
The Biopharmaceuticals Market size is estimated at USD 516.79 billion in 2024, and is expected to reach USD 761.80 billion by 2029, growing at a CAGR of 8.07% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the biopharmaceutical industry. Thus, biopharma industry trends shifted to most biopharmaceutical companies striving extensively to develop vaccines against the SARS-CoV-2 virus. For instance, in June 2022, Pfizer announced a USD 120 million investment for its Kalamazoo (Michigan) facility, enabling United States-based production for its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets). The increased interest in manufacturing COVID-19 vaccines significantly added to the growth of the biopharmaceutical industry during the COVID-19 pandemic. Following the stabilization from COVID-19, the increasing prevalence of chronic diseases is expected to further shift the biopharma industry trends toward developing solutions for chronic diseases, driving the growth of the biopharmaceutical industry.
Factors like rising chronic disease prevalence and increasing acceptance and demand for biopharmaceuticals owing to their ability to treat previously untreatable diseases are driving the market's growth. For instance, in September 2022, a report by the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually. The WHO also highlighted that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia. As per the same source, most people who develop Alzheimer's dementia are 65 years and above. Such a high disease prevalence is likely to facilitate the demand for effective treatment, which in turn will bolster biopharma market growth over the coming years.
The biopharmaceutical products' ability to address previously untreatable conditions has paved the way for introducing innovative drugs in the market. For instance, in September 2022, the Center for Biologics Evaluation and Research (CBER) approved Bluebird Bio, Inc.'s SKYSONA (elivaldogene autotemcel), which is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Similarly, in June 2022, CBER approved GlaxoSmithKline's PRIORIX, a live vaccine for measles, mumps, and rubella. Thus, such product approvals increase the availability of novel drugs in the market, which is expected to boost the biopharmaceutical industry over the forecast period.
Furthermore, in February 2022, Johnson and Johnson and its China-focused partner company Legend Biotech Corp. developed a therapy to treat white blood cell cancer type approved by the United States Food and Drug Administration (FDA). Thus, the development of new therapies that aid in treating oncologic disorders is anticipated to have a positive impact on the growth of the biopharmaceutical industry over the forecast period.
Thus, factors such as rising chronic disease prevalence, product launches, and approvals over the forecast period are likely to facilitate market growth over the forecast period. However, high-end manufacturing and complicated and cumbersome regulatory requirements will hinder biopharmaceuticals market growth over the forecast period.
Biopharmaceuticals Industry Segmentation
As per the scope of the report, biopharmaceuticals refer to any biologically synthesized molecules used to treat or manage disorders. These are derived by recombinant DNA technology and produced in bacterial, yeast, insect, plant, or mammalian cell expression systems, hybridomas, or primary or continuous cell lines.
The biopharmaceutical industry is segmented by product type (Monoclonal Antibodies (Anti-cancer Monoclonal Antibodies, Anti-inflammatory Monoclonal Antibodies, Other Monoclonal Antibodies), Recombinant Growth Factors (Erythropoietin, Granulocyte Colony Stimulating Factor), Purified Proteins (Leukemia Inhibitory Factor (LIF), P53 Protein, P38 Protein, Other Purified Proteins), Recombinant Proteins (Serum Albumin, Amyloid Protein, Defensin, Transferrin), Recombinant Hormones (Recombinant Human Growth Hormones, Recombinant Insulin, Other Recombinant Hormones), Vaccines (Recombinant Vaccines (Cancer Vaccine, Malaria Vaccine, Ebola Vaccine, Hepatitis-B Vaccine, Tetanus Vaccine, Diptheria Vaccine, Cholera Vaccine, Other Recombinant Vaccines), Conventional Vaccines (Polio Vaccine, Pox Vaccine, Other Conventional Vaccines)), Recombinant Enzymes (Enterokinase, Cyclase, Caspase, Cathepsin), Cell And Gene Therapies (Allogenic Products, Autologous Products, Acellular Products), Synthetic Immunomodulators (Cytokines, Interferons, and Interleukins), and Other Product Types), Therapeutic Application (Oncology, Inflammatory and infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, cardiovascular Diseases, Neurological Diseases, and Other Therapeutic Applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the biopharmaceuticals market sizes and trends for 17 countries across major regions globally.
The report offers the value in (USD) for the above-mentioned segments.
By Product Type | |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
|
By Therapeutic Application | |
Oncology | |
Inflammatory and Infectious Diseases | |
Autoimmune Disorders | |
Metabolic Disorders | |
Hormonal Disorders | |
Cardiovascular Diseases | |
Neurological Diseases | |
Other Therapeutic Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Biopharmaceuticals Market Size Summary
The biopharmaceutical industry has been growing significantly, mainly due to the impact of COVID-19, which has led to increased efforts by companies in the sector to develop vaccines. The market is also being driven by the rising prevalence of chronic diseases and the increasing acceptance and demand for biopharmaceuticals, which have the ability to treat previously untreatable diseases. The market's growth is further facilitated by the introduction of innovative drugs that address previously untreatable conditions. However, the industry faces challenges such as high-end manufacturing and complicated regulatory requirements. The biopharmaceutical market is experiencing significant growth in the anti-cancer monoclonal antibodies segment, with rising usage, growing approvals, clinical trials, and increasing research expenditure. The North America region holds a significant share of the market, driven by factors such as the growing burden of chronic diseases, rising geriatric population, and increasing investments in research and development activities. The presence of well-established biopharmaceutical companies and new product launches are also boosting the market growth in the region. The market is fragmented with several global and local companies operating, adopting various strategic measures such as acquisitions, partnerships, collaborations, and new product launches to expand their market presence.
Explore MoreBiopharmaceuticals Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Acceptance of and Huge Market Demand for Biopharmaceuticals
-
1.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
-
-
1.3 Market Restraints
-
1.3.1 High-end Manufacturing Requirements
-
1.3.2 Complicated and Cumbersome Regulatory Requirements
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product Type
-
2.1.1 Monoclonal Antibodies
-
2.1.1.1 Anti-cancer Monoclonal Antibodies
-
2.1.1.2 Anti-inflammatory Monoclonal Antibodies
-
2.1.1.3 Other Monoclonal Antibodies
-
-
2.1.2 Recombinant Growth Factors
-
2.1.2.1 Erythropoietin
-
2.1.2.2 Granulocyte Colony Stimulating Factor
-
-
2.1.3 Purified Proteins
-
2.1.3.1 Leukemia Inhibitory Factor (LIF)
-
2.1.3.2 P53 Protein
-
2.1.3.3 P38 Protein
-
2.1.3.4 Other Purified Proteins
-
-
2.1.4 Recombinant Proteins
-
2.1.4.1 Serum Albumin
-
2.1.4.2 Amyloid Protein
-
2.1.4.3 Defensin
-
2.1.4.4 Transferrin
-
-
2.1.5 Recombinant Hormones
-
2.1.5.1 Recombinant Human Growth Hormones
-
2.1.5.2 Recombinant Insulin
-
2.1.5.3 Other Recombinant Hormones
-
-
2.1.6 Vaccines
-
2.1.6.1 Recombinant Vaccines
-
2.1.6.1.1 Cancer Vaccine
-
2.1.6.1.2 Malaria Vaccine
-
2.1.6.1.3 Ebola Vaccine
-
2.1.6.1.4 Hepatitis-B Vaccine
-
2.1.6.1.5 Tetanus Vaccine
-
2.1.6.1.6 Diptheria Vaccine
-
2.1.6.1.7 Cholera Vaccine
-
2.1.6.1.8 Other Recombinant Vaccines
-
-
2.1.6.2 Conventional Vaccines
-
2.1.6.2.1 Polio Vaccine
-
2.1.6.2.2 Pox Vaccine
-
2.1.6.2.3 Other Conventional Vaccines
-
-
-
2.1.7 Recombinant Enzymes
-
2.1.7.1 Enterokinase
-
2.1.7.2 Cyclase
-
2.1.7.3 Caspase
-
2.1.7.4 Cathepsin
-
-
2.1.8 Cell and Gene Therapies
-
2.1.8.1 Allogenic Products
-
2.1.8.2 Autologous Products
-
2.1.8.3 Acellular Products
-
-
2.1.9 Synthetic Immunomodulators
-
2.1.9.1 Cytokines, Interferons, and Interleukins
-
-
2.1.10 Other Product Types
-
2.1.10.1 Blood Factors
-
2.1.10.2 Other Product Types
-
-
-
2.2 By Therapeutic Application
-
2.2.1 Oncology
-
2.2.2 Inflammatory and Infectious Diseases
-
2.2.3 Autoimmune Disorders
-
2.2.4 Metabolic Disorders
-
2.2.5 Hormonal Disorders
-
2.2.6 Cardiovascular Diseases
-
2.2.7 Neurological Diseases
-
2.2.8 Other Therapeutic Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Biopharmaceuticals Market Size FAQs
How big is the Biopharmaceuticals Market?
The Biopharmaceuticals Market size is expected to reach USD 516.79 billion in 2024 and grow at a CAGR of 8.07% to reach USD 761.80 billion by 2029.
What is the current Biopharmaceuticals Market size?
In 2024, the Biopharmaceuticals Market size is expected to reach USD 516.79 billion.